Authors

Latest:

Dr Miron on the Methods of Examining Molecular Alterations in Intraductal Carcinoma of the Prostate

Benjamin Miron, MD, discusses the methods utilized in a study of molecular alterations in patients with intraductal carcinoma of the prostate and the next steps for this research.

Christian Frederick Meyer, MD, PhD, MS

Latest:

Dr. Meyer on Standard Treatment Options in Cardiac Angiosarcoma

Christian Frederick Meyer, MD, PhD, MS, discusses standard treatment options in cardiac angiosarcoma.

Ajay Choudhri, MD

Latest:

Dr. Choudhri on the Impact of Artificial Intelligence in Cancer Care

Ajay Choudhri, MD, discusses the impact of developments in artificial intelligence in cancer care.

Goutham Narla, MD, PhD

Latest:

Dr. Narla on Advances Made With Precision Medicine in Oncology

Goutham Narla, MD, PhD, discusses advances made with precision medicine in oncology.

Nicole O. Williams, MD

Latest:

Dr. Williams on the Role of PI3K Inhibitors in HR+/HER2- Breast Cancer

Nicole O. Williams, MD, discusses the role of PI3K inhibitors in hormone receptor–positive, HER2-negative breast cancer.

Jeffrey V. Matous, MD

Latest:

Dr Matous on the Use Talquetamab/Pomalidomide in Relapsed/Refractory Multiple Myeloma

Jeffrey Matous, MD, discusses outcomes from the phase 1b MonumenTAL-2 trial with the combination of talquetamab and pomalidomide in patients with relapsed/refractory multiple myeloma.

Timothy Yap, MBBS, PhD, FRCP

Latest:

Dr Yap on the Continued Investigation of Saruparib in Advanced Solid Tumors

Timothy Yap, MBBS, PhD, FRCP, discusses next steps for investigating saruparib in advanced solid tumors with genetic mutations, including prostate cancer.

Scott S. Tykodi, MD, PhD

Scott Tykodi, MD, PhD, is an associate professor in the Clinical Research Division and an affiliate investigator in the Translational Science and Therapeutics Division at Fred Hutchinson Cancer Center.

Latest:

Dr Tykodi on the Current Limitations of Cabozantinib-Based Triplets in Advanced RCC

Scott Tykodi, MD, PhD, discusses the challenges with developing effective, less toxic triplet regimens for patients with advanced RCC.

Justine Yang Bruce, MD

Justine Yang Bruce, MD, is a faculty member in the Division of Hematology, Medical Oncology and Palliative Care within the Department of Medicine at the University of Wisconsin, as well as the director of the VA Medical Oncology Clinical Research Program and dhair of the Protocol Review and Monitoring Committee at the University of Wisconsin Carbone Cancer Center

Latest:

Toripalimab Plus De-Intensified Chemo Represents the Potential Future of Nasopharyngeal Cancer Management: With Justine Bruce, MD

Dr Bruce discusses treatment strategies for nasopharyngeal cancer, including how first-line toripalimab plus chemotherapy has shown improved OS.

Gustavo Rivero, MD

Gustavo Rivero, MD, is the director of translational research for myeloid disorders at Tampa General Hospital Cancer Institute in Florida and an associate professor of hematology/oncology.

Latest:

Targeting Menin: A New Frontier in Treating Refractory Leukemias

Incorporation of menin inhibitors is central to improving the outcome of difficult-to-treat leukemias.

Liat Hogen, MD, FRCSC

Latest:

Dr Hogen on Survival Outcomes With Neoadjuvant Chemotherapy and ICS in Epithelial Ovarian Cancer

Liat Hogen, MD, FRCSC, discusses the survival outcomes achieved with interval cytoreductive surgery following neoadjuvant chemotherapy in a study of patients with initial unresectable stage IV ovarian cancer.

Oleg Gluz, MD

Oleg Gluz, MD, is chief physician of Breast Cancer Niederrhein

Latest:

Dr Gluz on Ongoing Evaluations of De-Escalated Neoadjuvant Therapy in HR+/HER2+ Breast Cancer

Oleg Gluz, MD, discusses research assessing de-escalated chemotherapy and endocrine therapy combinations in HR-positive, HER2-positive early breast cancer.

Yoshiaki Nakamura, MD, PhD

Latest:

Concluding Remarks for the Current Use of ctDNA Testing for Treatment Decisions in stage II-III CRC

Yoshiaki Nakamura, MD, PhD, discusses the quantification threshold for tissue-free ctDNA in detecting residual tumor fractions, highlights additional mutations and hypermethylated loci identified by epigenomic assays, and examines how these assays complement current radiographic monitoring in stage II to III CRC while also considering their evolving role in identifying MRD to enhance recurrence-free survival.

Angela Tatiana Alistar, MD

Latest:

Dr. Alistar on the Need to Develop Biomarkers in Pancreatic Cancer

Angela Tatiana Alistar, MD, discusses the need to develop biomarkers in pancreatic cancer.

Frank Worden, MD

Latest:

Treating BRAF V600 and NTRK Gene Fusion Positivity

Amin Nassar, MD

Latest:

Bou Farhat and Nassar on the Use of NGS Mutation Signature vs IHC for Identifying dMMR Tumors

Drs Nassar and Bou Farhat explain how tumor-only NGS could address the limitations of IHC testing for MMR mutation signatures across several tumor types.

Albert Grinshpun, MD, MSc

Latest:

Dr Grinshpun on Ultra-Sensitive ctDNA Detection in HR+ Early Breast Cancer

Albert Grinshpun, MD, MSc, discusses the utility of ctDNA as a predictive biomarker of endocrine therapy sensitivity in patients with HR+ breast cancer.

Patricia Lugar, MD, MS, Duke Health

Latest:

Unmet Needs in SM Treatment

The panel of experts in SM highlight the unmet needs in the clinical care of systemic mastocytosis.

Rachel Kaufmann, PharmD

Latest:

LAG-3 Fills a Complex Role in the Immune System

The LAG-3 pathway has emerged as the next target for the use of immune checkpoint inhibitors in oncology.

Alan Tan, MD

Alan Tan, MD, is an associate professor of medicine in the Division of Hematology Oncology at Vanderbilt University Medical Center and a genitourinary oncology and melanoma specialist at Vanderbilt-Ingram Cancer Center in Nashville, Tennessee.

Latest:

Dr Tan on the Implications of Data From an Analysis of the PDIGREE Trial for Dual Checkpoint Blockade in ccRCC

Alan Tan, MD, discusses the clinical significance and next steps for evaluating the relative safety of IO vs IO/TKI regimens in ccRCC.